Moderna, Inc.
572 articles with Moderna, Inc.
-
Moderna and Medison Pharma Partner to Commercialize Moderna’s COVID-19 Vaccine Across Central Eastern Europe and Israel
6/7/2021
Moderna and Medison Pharma Partner to Commercialize Moderna’s COVID-19 Vaccine Across Central Eastern Europe and Israel
-
Moderna Announces Agreement to Supply the Republic of Botswana with its COVID-19 Vaccine
6/3/2021
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a supply agreement with the Government of the Republic of Botswana for Moderna’s vaccine against COVID-19, to support the government’s ongoing efforts to secure access to a COVID-19 vaccines for the people of Botswana
-
UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility
6/2/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, and UNICEF announced that they have signed a long-term agreement for the supply of COVID-19 vaccine on behalf of the COVAX Facility as part of the agreement announced in May 2021.
-
Moderna Announces New Drug Substance Production Agreement with Lonza in the Netherlands
6/2/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that it has entered into an additional agreement with Lonza to support drug substance manufacturing for its global supply chain.
-
A flurry of COVID-19 research news came out today. Here’s a look.
-
Moderna Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for the Moderna COVID-19 Vaccine
6/1/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for the licensure of its mRNA COVID-19 Vaccine to prevent COVID-19 in individuals 18 years of age and older.
-
Moderna Announces Agreement with Thermo Fisher Scientific for Fill/Finish Manufacturing of Moderna’s COVID-19 Vaccine
6/1/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has entered into an agreement with Thermo Fisher Scientific (NYSE: TMO) for fill/finish sterile manufacturing services and supply packaging for Moderna’s COVID-19 vaccine
-
The latest news in COVID-19 includes support for an investigation into the origins of the virus, a new naming system, and legal discussions of whether employers can mandate vaccination.
-
Moderna to Present at Upcoming Investor Conferences in June 2021
5/28/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences: Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:00 a.m. ET Goldman Sachs 42 nd Annual Healthcare Conference on Wednesday, June 9, 2021 at 8:00 a.m. ET
-
Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Fourth Annual Science Day
5/27/2021
Research includes innovations in lipid nanoparticle technology for mRNA delivery into hematopoietic stem and progenitor cells Intracellular event-guided rational design of lipid nanoparticle Assessment and prediction of SARS-CoV-2 variants for selection of COVID-19 booster vaccines
-
Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June
5/25/2021
Primary endpoint of non-inferior immunogenicity versus the Phase 3 study adult comparator group was met No cases of COVID-19 observed after two doses of vaccine using the primary case definition, consistent with a vaccine efficacy of 100% Safety and tolerability generally consistent with Phase 3 COVE study in adults; no significant safety concerns identified
-
Ocugen submitted a “Master File” to the U.S. FDA for COVAXIN, the vaccine that has already received authorization in India for people ages 12 and above.
-
Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline
5/24/2021
Moderna, Inc. and Aldevron, LLC have announced their expanded collaboration in support of the Moderna COVID-19 Vaccine and additional programs in Moderna’s clinical development pipeline.
-
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
-
Moderna and South Korea Explore Collaboration on mRNA Vaccines
5/22/2021
Moderna and South Korea will explore potential areas of collaboration for research and development of mRNA vaccines and local manufacturing opportunities in South Korea
-
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine
5/22/2021
The agreement will further enable global supply of mRNA-1273, Moderna's COVID-19 vaccine with Samsung Biologics' fill and finish manufacturing service
-
Japan’s Ministry of Health, Labour and Welfare (MHLW) Approves Moderna’s COVID-19 Vaccine
5/21/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that the Ministry of Health, Labour and Welfare of Japan granted special approval under article 14-3 of the Pharmaceuticals and Medical Devices Act for emergency use of Moderna’s mRNA COVID-19 vaccine, now known as COVID-19 Vaccine Moderna Intramuscular Injection, in Japan.
-
Moderna to Host Fourth Annual Science Day on May 27, 2021
5/19/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that it will host its virtual Science Day for analysts and investors at 8:00 a.m. ET on Thursday, May 27.
-
X-Vax Technology is preparing to submit an IND application to the U.S. FDA for its experimental vaccine against Herpes simplex virus 1 and 2 (HSV-1 and -2).
-
FDA says it is possible booster shots would be necessary for fully vaccinated individuals within a year even though vaccines are highly effective at COVID-19 prevention.